Neurogesx neurogesx.com


Public lists: Pharma Startups (4732)

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX- 4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes...Show all

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropa...Show all

Company (Acquired)

Phone: 650-358-3300

Fax:

2215 Bridgepointe Parkway
Suite 200
San Mateo, 94404
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Neurogesx $165.6M Apr 17, 2013
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Neurogesx Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
ARCH Venture PartnersVenture CapitalChicago, Illinois, United StatesPIPE, Unattributed VC, Series D, Series C, Series B, Series A
Alta PartnersVenture CapitalSan Francisco, California, United StatesUnattributed VC, Series D, Series C, Series B, Series A
Dow Venture CapitalCorporate VentureMidland, Michigan, United StatesUnattributed VC, Series D, Series C
Deerfield ManagementVenture CapitalNew York, New York, United StatesPIPE
Cross Creek AdvisorsPrivate EquitySalt Lake City, Utah, United StatesPIPE
See all 19 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 15 competitors